Mylan, Pliva, Actavis, and Lupin join Teva with generic Zoloft approvals.
With the expiration of Teva Pharmaceuticals’ 180-day market exclusivity on its generic version of Pfizer’s blockbuster depression drug, four companies are ready to enter this multibillion-dollar market.
Zoloft, indicated for depression and certain types of anxiety disorders, had U.S. sales of approximately $2.9 billion for the 12-month period ending Dec. 31, 2006, according to IMS Health. In 2005, Pfizer’s last full year on the market, sales reached $3.5 billion.
Mylan Pharmaceuticals, Pliva, Actavis Group, and Lupin Pharmaceuticals each received approval for sertraline hydrochloride tablets, 25 mg, 50 mg, and 100 mg.
